Transforming growth factor-beta1 inhibits expression of selenoprotein P in cultured human liver cells

FEBS Lett. 1999 Oct 22;460(1):23-6. doi: 10.1016/s0014-5793(99)01298-3.

Abstract

The effect of cytokines on the expression of selenoprotein P (SeP) in the human liver cell line HepG2 was investigated. Treatment with interleukin-1beta, interferon-gamma, and tumor necrosis factor-alpha had no effect on SeP levels in culture media or on SeP mRNA expression. Conversely, Western analysis revealed a dose-dependent reduction of SeP content in culture medium after treatment with transforming growth factor (TGF)-beta1 with an 1C50 of 31 pM. Treatment with 100 pM TGF-51 for 48 h led to a decrease to 21 +/- 9% of controls. RT-PCR analysis of SeP mRNA expression demonstrated an inhibition of SeP transcription to 40+/-2% of control levels after 24 h. The expression of a luciferase reporter construct under control of the human SeP promoter was downregulated by TGF-beta1 treatment in a dose-dependent fashion indicating a transcriptional regulation of the SeP gene by TGF-beta1.

MeSH terms

  • Cycloheximide / pharmacology
  • Down-Regulation / drug effects
  • Gene Expression Regulation / drug effects
  • Genes, Reporter
  • Humans
  • Interferon-gamma / pharmacology
  • Interleukin-1 / pharmacology
  • Liver / drug effects
  • Liver / metabolism*
  • Promoter Regions, Genetic
  • Proteins / metabolism*
  • RNA, Messenger
  • Reverse Transcriptase Polymerase Chain Reaction
  • Selenoprotein P
  • Selenoproteins
  • Transfection
  • Transforming Growth Factor beta / pharmacology*
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Interleukin-1
  • Proteins
  • RNA, Messenger
  • Selenoprotein P
  • Selenoproteins
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma
  • Cycloheximide